The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Novel therapies for myelofibrosis patients who have failed JAK inhibitors
Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, talks on the treatment options for patients with myelofibrosis who have failed JAK inhibitor therapy, highlighting the potential benefit of navitoclax therapy as an add-on therapy and in the frontline setting. Dr Kuykendall also comments on ongoing studies of ruxolitinib plus pelabresib, ruxolitinib plus navitoclax, ruxolitinib plus parsaclisib, and imetelstat, as well as the possibility of using luspatercept in the treatment of patients with myelofibrosis and anemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
